eli lilly and company retatrutide ESC 2024: improves lipid cardiovascular risk profile in Phase II trial Eli Lilly's Anticipated Weight Loss

What the pricing does not include MEDVi does not offer insurance billing

Moving beyond food noise to drug noise, GLP-1s are quieting the roar of addiction.

You're not just taking drops

Zheng, Journey L

It is increasingly discussed in longevity and preventive-medicine circles as a way to achieve: Metabolic balance without extreme appetite suppression Sustained tolerability by avoiding gastrointestinal side effects Lower cost and simplified maintenance regimens Long-term receptor engagement for cardiometabolic and neuroprotective benefits While this approach remains off-label and under formal investigation, the biological rationale is strong: GLP-1 signaling is not binary but dose-responsive, and even partial activation may influence inflammatory, vascular, and cognitive pathways linked to aging

WHG clients benefit from the level of attention we provide in regard to their experience and the compensation they recover